Medicine and Health Sciences Commons^™

Physicians’ Considerations And Practice Recommendations Regarding The Use Of Sodium-Glucose Cotransporter-2 Inhibitors, Serge A. Jabbour, Nasrien E. Ibrahim, Christos P. Argyropoulos

Division of Endocrinology, Diabetes and Metabolic Diseases Faculty Papers

Sodium-glucose cotransporter-2 inhibitors (SGLT-2is) (canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin), although initially developed as glucose-lowering drugs, provide significant beneficial effects on cardiorenal outcomes, including heart failure, regardless of type 2 diabetes status. Integration of SGLT-2is into clinical practice requires practical guidance for physicians about their use. To overcome physicians’ clinical inertia for SGLT-2i use, including addressing safety, potentially a barrier to their use, a roundtable discussion with physicians from three specialties (cardiology, endocrinology, and nephrology) was conducted. This review summarizes the physicians’ clinical experience and recommendations about SGLT-2i use across different patient populations, taking into consideration the beneficial effects of SGLT-2is …